[Alphacalcidol in the treatment of osteopenic syndrome in patients with bronchial asthma].
OBJECTIVE
To assess effectiveness of alphacalcidol in the treatment of osteopenic syndrome in patients with bronchial asthma (BA).


METHODS
65 BA patients with low densitometric parameters of bone tissue density were examined for bone density, basic parameters of Ca-P metabolism and some markers of bone metabolism during 6-month therapy with alphacalcidol (alpha-D3-TEVA) in a dose 0.5-0.75 mcg/day.


RESULTS
All the patients after 6 months of therapy experienced pain relief, normalization of calcium-phosphorus metabolism, lower risk of broken bones. Their bone tissue increased its density.


CONCLUSIONS
Alphacalcidol has analgetic and antiresorptive properties. It effectively prevents and treats osteopenic syndrome in patients with bronchial asthma.
Kochetkova
E A
EA
Gel'tser
B I
BI
D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000473:pathology; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000188:drug therapy*; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D017553:Phosphorus Compounds / Q000097:blood; D011788:Quality of Life; D013577:Syndrome
D018927:Anti-Asthmatic Agents; D005938:Glucocorticoids; D006887:Hydroxycholecalciferols; D017553:Phosphorus Compounds; D002118:Calcium; C008088:alfacalcidol